Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis

Infectious Diseases

Volumn 47, Issue 6, 2015, Pages 379-384

  Ruggero, Michael A ^a   Peaper, David R ^b   Topal, Jeffrey E ^a,b  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteremia; Infective endocarditis; MRSA; Salvage therapy; Telavancin

Indexed keywords

DAPTOMYCIN; TELAVANCIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL GROWTH; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MITRAL VALVE; MONOTHERAPY; MORTALITY RATE; OVERALL SURVIVAL; REFRACTORY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; AGED; BACTEREMIA; CASE REPORT; DRUG EFFECTS; ENDOCARDITIS, BACTERIAL; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; SALVAGE THERAPY; STAPHYLOCOCCAL INFECTIONS; SURVIVAL RATE; TIME; YOUNG ADULT;

ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STAPHYLOCOCCAL INFECTIONS; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84941561739     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365548.2014.995696     Document Type: Article

References (26)

1. Van Hal SJ, Lodise T P, Paterson DL The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and metaanalysis Clin Infect Dis 2012; 54: 755-71.
2. Soriano A, Marco F, Martinez J A, Pisos E, Almela M, Dimova VP, et al Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 2008; 46: 193-200.
3. Neuner EA, Casabar E, Reichley R, McKinnon PS Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant bacteremia Diagn Microbiol Infect Dis 2010; 67: 228-33.
4. Holmes N E, Turnidge J D, Munckhof W J, Robinson J O, Korman TM, O' Sullivan MVN, et al Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations J Infect Dis 2011; 204: 340-7.
5. Lodise T P, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia and treated with vancomycin Antimicrob Agents Chemother 2008; 52: 3315-20.
6. F owler VG, Boucher HW, Corey RG, Abrutyn E, Karchmer AW, Rupp ME, et al Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus N Engl J Med 2006; 355: 653-65.
7. Baddour LM, W ilson WR, Bayer A S, Fowler VG, Bolger A F, Levison ME, et al Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications AHA scientific statement Circulation 2005; 111: e394-434.
8. Mylonakis E, Calderwood SB Infective endocarditis in adults N Engl J Med 2001; 345: 1318-30.
9. Boucher H W, Sakoulas G.Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus Clin Infect Dis 2007; 45: 601-8.
10. Stryjewski M E, Graham D R, W ilson S E, O' R iordan W, Young D, Lentnek A, et al Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms Clin Infect Dis 2008; 46: 1683-93.
11. Rubinstein E, Lalani T, Corey GR, Kanafani Z A, Nannini EC, Rocha MG, et al Telavancin versus vancomycin for hospitalacquired pneumonia due to Gram-positive pathogens Clin Infect Dis 2011; 52: 31-40.
12. Saravolatz LD, Stein GE, Johnson LB Telavancin: a novel lipoglycopeptide Clin Infect Dis 2009; 49: 1908-14.
13. MacGowan AP, Noel AR, Tomaselli S, Elliot HC, Bowker KE Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection Antimicrob Agents Chemother 2011; 55: 867-73.
14. Leonard SN, Vidaillac C, Rybak MJ Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations Antimicrob Agents Chemother 2009; 53: 2928-33.
15. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, et al Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 2005; 49: 1127-34.
16. Lunde C S, Rexer C H, Hartouni S R, Axt S, Benton B M.Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus Antimicrob Agents Chemother 2010; 54: 2198-200.
17. Mendes R E, Sader H S, Farrell D J, Jones R N.W orldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents Antimicrob Agents Chemother 2010; 56: 3999-4004.
18. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 2004; 42: 2398-402.
19. Steed ME, Vidaillac C, Rybak MJ Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model Antimicrob Agents Chemother 2011; 54: 955-9.
20. Kosowska-Shick K, Clark C, Pankuch G A, McGhee P, Dewasse B, Beachel L, et al Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies Antimicrob Agents Chemother 2019; 53: 4217-24.
21. Xiong Q, Hady WA, Bayer A S, Chen L, Kreiswirth BN, Yang SJ Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus Clin Infect Dis 2011; 56: 5528-33.
22. Madrigal AG, Basuino L, Chambers H F.Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus Antimicrob Agents Chemother 2005; 49: 3163-5.
23. Marcos L A, Camins B C.Successful treatment of vancomycin-intermediate staphylococcus aureus pacemaker lead infective endocarditis with telavancin Antimicrob Agents Chemother 2010; 54: 5376-8.
24. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, et al Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis Clin Infect Dis 2000; 30: 633-8.
25. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing Twenty-first informational supplement M100-S21 Wayne, PA: CLSI; 2011.
26. Cosgrove SE, Fowler VG Management of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 2008; 46: S386-93.